TUESDAY, Sept. 30 (HealthDay News) -- A variation of the adiponectin (ADIPOQ) gene is associated with a significantly decreased risk of colorectal cancer, according to a report published in the Oct. 1 issue of the Journal of the American Medical Association.
Virginia G. Kaklamani, M.D., of the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues conducted two case-control studies: the first included 441 cases and 658 matched controls (all of Ashkenazi Jewish ancestry); the second included 199 cases and 199 matched controls from Chicago.
The researchers found that one single-nucleotide polymorphism (SNP) -- rs266729 -- was associated with a significantly decreased risk of colorectal cancer in both studies (odds ratios 0.72 and 0.52, respectively). Their combined analysis of the two studies found an adjusted odds ratio of 0.73.
"If these exciting results can be confirmed in other studies, the adiponectin axis may emerge as an important modifier of colorectal cancer risk," the authors conclude. "Future studies will need to address the potential impact of adiponectin and its SNPs in the prognosis of colorectal cancer and also may be incorporated in genetic risk models for the disease."
Abstract
Full Text
